<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布给投资者的报告中，Canaccord Genuity Group 将其目标价格从 152.00 美元下调至 124.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Canaccord Genuity Group 的价格目标显示出从公司当前价格的潜在上涨幅度为 70.05%。</p>
<p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
<ul>
<li>中型股奇迹：3 只在 5 月超越销售预期的股票</li>
</ul>
<p>其他研究分析师最近也发布了关于该公司的研究报告。Stifel Nicolaus 将 TransMedics Group 的目标价格从 130.00 美元下调至 85.00 美元，并在周三的研究报告中对该公司给予 “持有” 评级。Wall Street Zen 在 2 月 28 日的报告中将 TransMedics Group 的评级从 “买入” 下调至 “持有”。TD Cowen 在周三的报告中将 TransMedics Group 的目标价格从 190.00 美元下调至 120.00 美元，并对该股票给予 “买入” 评级。摩根大通在 2 月 25 日的报告中将 TransMedics Group 的目标价格从 114.00 美元上调至 149.00 美元，并给予公司 “中性” 评级。最后，Piper Sandler 在周三的报告中将 TransMedics Group 的目标价格从 160.00 美元下调至 120.00 美元，并对该股票给予 “增持” 评级。六位分析师对该股票给予 “买入” 评级，六位分析师给予公司 “持有” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 135.00 美元。</p>
<p><strong>阅读我们最新的 TMDX 股票报告</strong></p>
<h2>TransMedics Group 股票表现</h2>
<ul>
<li>3 只在 2025 年表现优异的医疗技术股票</li>
</ul>
<p>在周三的交易时段，TMDX 股价下跌 22.01 美元，跌至 72.92 美元。该股票的交易量为 7,727,054 股，而其平均交易量为 979,563 股。TransMedics Group 的一年低点为 70.00 美元，一年高点为 156.00 美元。该公司的 50 日简单移动平均线为 116.57 美元，200 日简单移动平均线为 125.96 美元。该公司的速动比率为 6.59，流动比率为 7.14，债务与股本比率为 1.06。该股票的市值为 25.2 亿美元，市盈率为 14.88，贝塔值为 2.07。</p>
<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最近在 5 月 5 日发布了其财报。公司报告本季度每股收益为 0.30 美元，低于市场共识预期的 0.62 美元，差额为 0.32 美元。TransMedics Group 的股本回报率为 30.17%，净利润率为 31.43%。该公司本季度的收入为 1.7393 亿美元，而市场共识预期为 1.7448 亿美元。在去年同期，该公司每股收益为 0.70 美元。与去年同期相比，该季度的收入增长了 21.2%。股票分析师预计 TransMedics Group 今年将发布每股收益 2.48 美元。</p>
<h2>内部活动</h2>
<ul>
<li>3 只高增长股票，交易者热爱，投资者应关注</li>
</ul>
<p>在其他新闻中，内部人士 Nicholas Corcoran 于 3 月 2 日星期一出售了 2,966 股 TransMedics Group 股票，交易价格为每股 139.12 美元，总价值为 412,629.92 美元。出售后，该内部人士直接持有公司 29,831 股股票，价值约为 4,150,088.72 美元。此交易代表其持股减少了 9.04%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Anil P. Ranganath 于 3 月 2 日星期一出售了 864 股 TransMedics Group 股票，交易价格为每股 139.12 美元，总价值为 120,199.68 美元。出售完成后，该内部人士持有公司 13,091 股股票，价值约为 1,821,219.92 美元。这代表其持股减少了 6.19%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了价值 2,353,002 美元的 16,205 股公司股票。公司内部人士持有 6.90% 的公司股票。</p>
<h2>机构投资者对 TransMedics Group 的看法</h2>
<p>几家对冲基金最近增加或减少了在 TMDX 的持股。加拿大皇家银行在第一季度将其在 TransMedics Group 的持股增加了 47.9%。加拿大皇家银行目前拥有 26,582 股公司股票，价值 1,788,000 美元，此前在上一季度增持了 8,604 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 TransMedics Group 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 19,525 股公司股票，价值 1,314,000 美元，此前在上一季度增持了 868 股。高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团目前拥有 507,510 股公司股票，价值 34,145,000 美元，此前在上一季度增持了 86,721 股。拉塞尔投资集团在第二季度将其在 TransMedics Group 的持股增加了 13.5%。拉塞尔投资集团目前拥有 7,901 股公司股票，价值 1,059,000 美元，此前在上一季度增持了 938 股。最后，M&amp;T 银行在第二季度购买了 TransMedics Group 的新头寸，价值 209,000 美元。99.67% 的股票由机构投资者持有。</p>
<h2>TransMedics Group 新闻汇总</h2>
<p>以下是本周影响 TransMedics Group 的主要新闻故事：</p>
<ul>
<li>积极情绪：季度收入增长和持续的产品需求——TMDX 发布的第一季度收入同比增长约 21%，得益于其器官护理系统（OCS）的强劲需求，显示出持续的收入增长势头。PR Newswire：第一季度业绩</li>
<li>积极情绪：尽管下调目标价，一些分析师仍然看涨——多家机构下调了目标价，但仍维持买入/增持评级（例如，TD Cowen、Piper Sandler、Needham），这表明一些投资者仍然看到长期采用的多季度上涨空间。Benzinga：分析师笔记</li>
<li>中性情绪：指导方针更新——管理层发布了 2026 财年的收入指导，范围与华尔街共识相符（大约 7.27 亿至 7.57 亿美元，华尔街共识为 7.39 亿美元），对利润率和每股收益的执行敏感性留下了一些模糊性。幻灯片/新闻稿</li>
<li>中性情绪：财报电话会议记录可用——管理层关于采用、物流增长和利润驱动因素的评论可供投资者审阅，以寻找持久改善的迹象。Seeking Alpha：电话会议记录</li>
<li>消极情绪：每股收益显著低于预期和利润率压力——TMDX 报告每股收益为 0.30 美元，而共识为约 0.62 美元，并指出利润率下降，这是近期股价下跌的主要催化剂。Zacks：第一季度业绩不及预期及利润率</li>
<li>消极情绪：分析师下调评级和目标价——多家机构下调了目标价，至少一家将 TMDX 的评级下调至市场表现，尽管仍有一些买入评级，但加大了卖压。Finviz：分析师行动</li>
<li>消极情绪：市场反应：交易量大且估值重置——每股收益不及预期、利润率担忧和分析师重新评级的结合导致交易量上升，并迅速重新定价，相较于近期移动平均线。Zacks：业绩和收入不及预期</li>
</ul>
<h2>TransMedics Group 公司简介</h2>
<p>(获取免费报告)</p>
<p>TransMedics Group, Inc 是一家总部位于马萨诸塞州安多佛的医疗设备公司，专注于用于移植的先进器官保存和运输系统。该公司的旗舰技术器官护理系统（OCS）在运输过程中保持供体器官处于接近生理的温暖跳动状态，旨在延长保存时间并改善移植后的结果。TransMedics 的解决方案满足了移植中一个关键需求，通过减少缺血损伤和扩大供体器官池来解决问题。</p>
<p>TransMedics 目前市场上有两个商业化的 OCS 平台。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们认为比 TransMedics Group 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
<p>在你考虑 TransMedics Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 TransMedics Group 并不在名单上。</p>
<p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TMDX

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>Canaccord Genuity Group 将 TransMedics Group (NASDAQ:TMDX) 的目标价从 152.00 美元下调至 124.00 美元，同时维持 “买入” 评级。这个新目标暗示从当前价格来看有 70.05% 的潜在上涨空间。其他分析师也调整了他们的评级，有些下调了目标价，有些则维持或改变了评级。该股票最近交易价格为 72.92 美元，市值为 25.2 亿美元。公司在上个季度报告的收入为 1.7393 亿美元，略微低于预期</p>

<p>TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price dropped by equities researchers at Canaccord Genuity Group from $152.00 to $124.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. Canaccord Genuity Group's price objective points to a potential upside of 70.05% from the company's current price.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周三发布给投资者的报告中，Canaccord Genuity Group 将其目标价格从 152.00 美元下调至 124.00 美元，Benzinga 报道。该券商目前对该股票给予 “买入” 评级。Canaccord Genuity Group 的价格目标显示出从公司当前价格的潜在上涨幅度为 70.05%。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股奇迹：3 只在 5 月超越销售预期的股票</li>
</ul>
</div><p>Other research analysts also recently issued research reports about the company. Stifel Nicolaus cut their target price on TransMedics Group from $130.00 to $85.00 and set a &#34;hold&#34; rating for the company in a research note on Wednesday. Wall Street Zen cut TransMedics Group from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, February 28th. TD Cowen lowered their price target on TransMedics Group from $190.00 to $120.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday. JPMorgan Chase &amp; Co. raised their price target on TransMedics Group from $114.00 to $149.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, February 25th. Finally, Piper Sandler lowered their price target on TransMedics Group from $160.00 to $120.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average target price of $135.00.</p>
<div class="lb-trans"><p>其他研究分析师最近也发布了关于该公司的研究报告。Stifel Nicolaus 将 TransMedics Group 的目标价格从 130.00 美元下调至 85.00 美元，并在周三的研究报告中对该公司给予 “持有” 评级。Wall Street Zen 在 2 月 28 日的报告中将 TransMedics Group 的评级从 “买入” 下调至 “持有”。TD Cowen 在周三的报告中将 TransMedics Group 的目标价格从 190.00 美元下调至 120.00 美元，并对该股票给予 “买入” 评级。摩根大通在 2 月 25 日的报告中将 TransMedics Group 的目标价格从 114.00 美元上调至 149.00 美元，并给予公司 “中性” 评级。最后，Piper Sandler 在周三的报告中将 TransMedics Group 的目标价格从 160.00 美元下调至 120.00 美元，并对该股票给予 “增持” 评级。六位分析师对该股票给予 “买入” 评级，六位分析师给予公司 “持有” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 135.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on TMDX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 TMDX 股票报告</strong></p>
</div><h2>TransMedics Group Stock Performance</h2>
<div class="lb-trans"><h2>TransMedics Group 股票表现</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只在 2025 年表现优异的医疗技术股票</li>
</ul>
</div><p>TMDX traded down $22.01 during trading hours on Wednesday, hitting $72.92. The stock had a trading volume of 7,727,054 shares, compared to its average volume of 979,563. TransMedics Group has a 1 year low of $70.00 and a 1 year high of $156.00. The company's fifty day simple moving average is $116.57 and its 200 day simple moving average is $125.96. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The stock has a market cap of $2.52 billion, a PE ratio of 14.88 and a beta of 2.07.</p>
<div class="lb-trans"><p>在周三的交易时段，TMDX 股价下跌 22.01 美元，跌至 72.92 美元。该股票的交易量为 7,727,054 股，而其平均交易量为 979,563 股。TransMedics Group 的一年低点为 70.00 美元，一年高点为 156.00 美元。该公司的 50 日简单移动平均线为 116.57 美元，200 日简单移动平均线为 125.96 美元。该公司的速动比率为 6.59，流动比率为 7.14，债务与股本比率为 1.06。该股票的市值为 25.2 亿美元，市盈率为 14.88，贝塔值为 2.07。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.48 million. During the same quarter in the prior year, the business earned $0.70 EPS. The firm's revenue for the quarter was up 21.2% compared to the same quarter last year. Equities analysts anticipate that TransMedics Group will post 2.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最近在 5 月 5 日发布了其财报。公司报告本季度每股收益为 0.30 美元，低于市场共识预期的 0.62 美元，差额为 0.32 美元。TransMedics Group 的股本回报率为 30.17%，净利润率为 31.43%。该公司本季度的收入为 1.7393 亿美元，而市场共识预期为 1.7448 亿美元。在去年同期，该公司每股收益为 0.70 美元。与去年同期相比，该季度的收入增长了 21.2%。股票分析师预计 TransMedics Group 今年将发布每股收益 2.48 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高增长股票，交易者热爱，投资者应关注</li>
</ul>
</div><p>In other news, insider Nicholas Corcoran sold 2,966 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the sale, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the completion of the sale, the insider owned 13,091 shares in the company, valued at approximately $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Nicholas Corcoran 于 3 月 2 日星期一出售了 2,966 股 TransMedics Group 股票，交易价格为每股 139.12 美元，总价值为 412,629.92 美元。出售后，该内部人士直接持有公司 29,831 股股票，价值约为 4,150,088.72 美元。此交易代表其持股减少了 9.04%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Anil P. Ranganath 于 3 月 2 日星期一出售了 864 股 TransMedics Group 股票，交易价格为每股 139.12 美元，总价值为 120,199.68 美元。出售完成后，该内部人士持有公司 13,091 股股票，价值约为 1,821,219.92 美元。这代表其持股减少了 6.19%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了价值 2,353,002 美元的 16,205 股公司股票。公司内部人士持有 6.90% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On TransMedics Group</h2>
<div class="lb-trans"><h2>机构投资者对 TransMedics Group 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in TMDX. Royal Bank of Canada boosted its holdings in TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock worth $1,314,000 after acquiring an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock worth $1,059,000 after purchasing an additional 938 shares during the last quarter. Finally, M&amp;T Bank Corp purchased a new position in shares of TransMedics Group in the second quarter worth $209,000. 99.67% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了在 TMDX 的持股。加拿大皇家银行在第一季度将其在 TransMedics Group 的持股增加了 47.9%。加拿大皇家银行目前拥有 26,582 股公司股票，价值 1,788,000 美元，此前在上一季度增持了 8,604 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 TransMedics Group 的持股增加了 4.7%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 19,525 股公司股票，价值 1,314,000 美元，此前在上一季度增持了 868 股。高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团目前拥有 507,510 股公司股票，价值 34,145,000 美元，此前在上一季度增持了 86,721 股。拉塞尔投资集团在第二季度将其在 TransMedics Group 的持股增加了 13.5%。拉塞尔投资集团目前拥有 7,901 股公司股票，价值 1,059,000 美元，此前在上一季度增持了 938 股。最后，M&amp;T 银行在第二季度购买了 TransMedics Group 的新头寸，价值 209,000 美元。99.67% 的股票由机构投资者持有。</p>
</div><h2>TransMedics Group News Roundup</h2>
<div class="lb-trans"><h2>TransMedics Group 新闻汇总</h2>
</div><p>Here are the key news stories impacting TransMedics Group this week:</p>
<div class="lb-trans"><p>以下是本周影响 TransMedics Group 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Quarterly revenue growth and continued product demand — TMDX posted Q1 revenue up ~21% year‑over‑year driven by strong demand for its Organ Care System (OCS), showing continued top‑line momentum. PR Newswire: Q1 Results</li>
<li>Positive Sentiment: Some analysts remain bullish despite cuts — Several firms trimmed price targets but retained buy/overweight stances (e.g., TD Cowen, Piper Sandler, Needham), signaling that some investors still see multi‑quarter upside from long‑term adoption. Benzinga: Analyst Notes</li>
<li>Neutral Sentiment: Guidance updated — Management issued FY‑2026 revenue guidance in a range that brackets Wall Street consensus (roughly $727M–$757M vs. $739M consensus), leaving some ambiguity about margin and EPS sensitivity to execution. Slide Deck / Press Release</li>
<li>Neutral Sentiment: Earnings call transcript available — Management commentary on adoption, logistics growth and margin drivers is available for investors to review for signs of durable improvement. Seeking Alpha: Call Transcript</li>
<li>Negative Sentiment: Significant EPS miss and margin pressure — TMDX reported $0.30 EPS vs. ~$0.62 consensus and noted falling margins, which is the primary near‑term catalyst for the share decline. Zacks: Q1 Miss &amp; Margins</li>
<li>Negative Sentiment: Analyst downgrades and price‑target cuts — Multiple firms cut targets and at least one downgraded TMDX to market‑perform, amplifying selling pressure despite some retained buy ratings. Finviz: Analyst Actions</li>
<li>Negative Sentiment: Market reaction: heavy volume and reset valuation — The combination of the EPS miss, margin concerns and analyst re‑rating produced elevated trading and a rapid re‑pricing versus recent moving averages. Zacks: Earnings &amp; Revenue Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：季度收入增长和持续的产品需求——TMDX 发布的第一季度收入同比增长约 21%，得益于其器官护理系统（OCS）的强劲需求，显示出持续的收入增长势头。PR Newswire：第一季度业绩</li>
<li>积极情绪：尽管下调目标价，一些分析师仍然看涨——多家机构下调了目标价，但仍维持买入/增持评级（例如，TD Cowen、Piper Sandler、Needham），这表明一些投资者仍然看到长期采用的多季度上涨空间。Benzinga：分析师笔记</li>
<li>中性情绪：指导方针更新——管理层发布了 2026 财年的收入指导，范围与华尔街共识相符（大约 7.27 亿至 7.57 亿美元，华尔街共识为 7.39 亿美元），对利润率和每股收益的执行敏感性留下了一些模糊性。幻灯片/新闻稿</li>
<li>中性情绪：财报电话会议记录可用——管理层关于采用、物流增长和利润驱动因素的评论可供投资者审阅，以寻找持久改善的迹象。Seeking Alpha：电话会议记录</li>
<li>消极情绪：每股收益显著低于预期和利润率压力——TMDX 报告每股收益为 0.30 美元，而共识为约 0.62 美元，并指出利润率下降，这是近期股价下跌的主要催化剂。Zacks：第一季度业绩不及预期及利润率</li>
<li>消极情绪：分析师下调评级和目标价——多家机构下调了目标价，至少一家将 TMDX 的评级下调至市场表现，尽管仍有一些买入评级，但加大了卖压。Finviz：分析师行动</li>
<li>消极情绪：市场反应：交易量大且估值重置——每股收益不及预期、利润率担忧和分析师重新评级的结合导致交易量上升，并迅速重新定价，相较于近期移动平均线。Zacks：业绩和收入不及预期</li>
</ul>
</div><h2>TransMedics Group Company Profile</h2>
<div class="lb-trans"><h2>TransMedics Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.</p>
<div class="lb-trans"><p>TransMedics Group, Inc 是一家总部位于马萨诸塞州安多佛的医疗设备公司，专注于用于移植的先进器官保存和运输系统。该公司的旗舰技术器官护理系统（OCS）在运输过程中保持供体器官处于接近生理的温暖跳动状态，旨在延长保存时间并改善移植后的结果。TransMedics 的解决方案满足了移植中一个关键需求，通过减少缺血损伤和扩大供体器官池来解决问题。</p>
</div><p>TransMedics currently markets two commercially available OCS platforms.</p>
<div class="lb-trans"><p>TransMedics 目前市场上有两个商业化的 OCS 平台。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 TransMedics Group 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TransMedics Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 TransMedics Group 并不在名单上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

Market Beat

TransMedics

Stifel Financial

Toronto Dominion Bank

摩根大通

Piper Sandler Cos

加拿大皇家银行

高盛

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

TransMedics Group（纳斯达克股票代码：TMDX）被 Canaccord Genuity Group 给予新的 124.00 美元目标价